Syndecan-1, as an emerging biomarker for both heart failure and liver fibrosis, could find its usefulness either in the initial assessment or the long-term prognosis in a large number of patients with concomitant cardiac and hepatic diseases. Here, SDC1 is linked to Hepatic fibrosis.